Urine Cystatin C Determination in the Establishment of Reference Interval in the Diagnosis and Treatment of Renal Injury ()
1. INTRODUCTION
Cystatin C is a small molecular weight cystine protease inhibitor, which is expressed by all nucleated cells in the body with a constant production rate [ 1 ]. Under normal physiological conditions, Cystatin C can be freely filtered from the glomerulus with plasma, and can be completely reabsorbed by renal tubular epithelial cells and degraded in the cell without returning to the blood; however, tubular epithelial cells do not secrete cystatin c to the lumen. Therefore, serum cystatin C is used as a functional indicator of glomerular filtration rate [ 2 - 6 ]. However, when renal tubular function is impaired, cystatin C is impaired in renal tubular reabsorption, and the concentration of cystatin C in the urine increases. At this time, cystatin C in urine is used as an important indicator for evaluating renal tubular function. However, at present, the detection of renal function is mostly based on the detection of serum cystatin C. The recent findings of primary glomerular diseases or renal vascular diseases and other diseases are also accompanied by different degrees of tubular interstitial damage, and the severity of damage is directly related to the speed of development and prognosis of kidney disease. At this time, detecting the concentration of cystatin C in the urine is a very sensitive indicator reflecting the damage of the renal tubules [ 7 - 9 ]. However, there are still controversies about the standardization and uniform reference interval for the detection of urinary cystatin C in clinical practice. Therefore, this research group investigated the urine cystatin C concentration of patients with kidney injury, and calculated the baseline level of urine cystatin C in patients with kidney injury; established the diagnostic concentration interval of urine cystatin C and the control level of urine cystatin C for patients with kidney injury, to help promote the establishment of standardization of urine cystatin C detection.
2. MATERIALS AND METHODS
2.1. Research Subjects
150 urine and blood specimens of patients who were hospitalized in this hospital from January to September 2021 and confirmed kidney injury were selected as the research subjects, that is, the kidney injury group, and other basic diseases were excluded; In addition, 150 urine and blood specimens of healthy people who underwent physical examinations in the physical examination center of this hospital during the same period were selected as the control group, which is the healthy control group. The basic data of the two groups, such as gender, age, occupation, etc., are basically the same. Urine samples were collected according to the sample collection specification and stored in −20˚C refrigerator; Blood samples were collected by taking 2 ml of fasting venous whole blood, centrifuging at 4000 rpm for 10 minutes, and the serum was stored in the refrigerator at −20˚C. After all samples were collected, they were tested uniformly. The research will be carried out after the approval of the medical ethics committee of the hospital.
2.2. Research Methods
Research object grouping: 1) Healthy control group: 150 cases, aged 17 to 70 years old, excluded hypertension, diabetes, hyperlipidemia, cardiovascular, kidney and other diseases that affect renal function, and blood and urine routines are normal Healthy people. 2) Collect at least 150 patients with kidney disease as judged by “Diagnosis of Kidney”. 3) Detect the urine and blood cystatin C levels of the above two groups, and analyze the urine cystatin C concentration range of patients with different degrees of nephropathy. Compare with the detection method of serum cystatin C to determine the control level of urinary cystatin C.
2.3. Implementation Plan
Collect urine specimens of all research subjects, and use the kit of Beijing Jiuqiang Biotechnology Co., Ltd. to detect the level of cystatin C. This topic mainly uses the automatic biochemical analyzer Hitachi 7180 to test patient samples and issue test results.
2.4. Reference Interval
The reference interval of serum cystatin C is 0.6 - 2.5 mg/l.
2.5. Statistical Analysis
The SPSS22.0 statistical software was used for analysis. The comparison of the number of cases between the two groups was performed by chi-square test; the comparison of cystatin C values was performed by t test, and P < 0.05 was considered statistically significant.
3. RESULTS
After testing the blood and urine cystatin C of 300 study subjects, it was found that the urine and blood cystatin C of the kidney injury group were significantly higher than those of the healthy control group. Compared the results of the two groups, the t values were 5.3210 and 5.7399, respectively. The P value is 0.0000, the difference is statistically significant; the comparison of urine and blood cystatin C in the kidney injury group, t = 3.4600, P = 0.0003; the comparison of urine and blood cystatin C in the healthy control group, t = 42.7744, P = 0.0000.
The specific results are shown in Table 1 below.
4. DISCUSSION
Cystatin C is an alkaline, non-glycosylated protein, which can be expressed constantly and continuously in all cell nuclei and does not fluctuate over time. Cystatin C can freely pass through the glomerular filter membrane in the physiological environment, and is almost completely reabsorbed and degraded in the renal tubules, without recirculation, and the renal tubules will not secrete Cystatin C. Under normal physiological conditions, the concentration of cystatin C in urine is very low, only 5% to 10% in blood. However, when the renal tubules are damaged and dysfunction occurs, the concentration of cystatin C in the urine increases [ 10 ].
The clinical evaluation of renal function indicators is generally based on the glomerular filtration rate as the standard. Markers of endogenous glomerular filtration rate are serum creatinine, urea, β2-microglobulin, β-trace protein and cystatin C. Among them, Cystatin C is more reliable and accurate than other indicators.
Table 1. The application of urine cystatin C in renal impairment.
Most of the current cystatin C detection methods and samples are mainly serum cystatin C, but cystatin C in urine samples are less studied, and the standardization and stability of urine cystatin C detection and the unified reference interval are clinically controversial [ 11 , 12 ]. Therefore, this research group investigated the urine cystatin C concentration of patients with kidney injury, and calculated the baseline level of urine cystatin C in patients with kidney injury, and established the diagnostic concentration interval of urinary cystatin C and the control level of urine cystatin C for patients with kidney injury, and help promote the establishment of standardization and stability of urine cystatin C detection.
The results of this study showed that the blood and urine cystatin C of the kidney injury group was significantly higher than that of the healthy control group. The difference between the two groups was statistically significant, P < 0.001; the blood cystatin C of the two groups was significantly higher than the urine Cystatin C; blood cystatin C and urine cystatin C were compared between the two groups, and the differences were statistically significant, P < 0.01. The reference interval of urinary cystatin C is lower than that of blood, and can be established uniformly based on multi-center studies.
5. CONCLUSION
By investigating the urine cystatin C concentration of patients with kidney injury, whether it is kidney injury or healthy controls, urine cystatin C is significantly lower than blood cystatin C. Through multicenter study of the baseline levels of urinary cystatin C in the population of kidney injury patients, it establishes the diagnostic concentration interval of urinary cystatin C and the control levels of detecting urine cystatin C in kidney injury patients, to help promote the detection standardization and stability establishment of urinary cystatin C.
LIMITATIONS OF THE STUDY
All the research subjects in this study are from the inpatients in this hospital and the healthy population of the physical examination center. There are certain regional differences and it cannot fully represent the situation in other regions, so it has certain limitations.
ACKNOWLEDGEMENTS
This project has been approved, and has received strong support from the functional departments of the hospital and the help of colleagues. I would like to express my heartfelt thanks for their support and help! I wish them good health, smooth work and all the best!
FUNDING PROJECT
The clinical application value of urine sample detection CYS-C as a sub-project of the national key research and development plan “National Quality Basic Common Technology Research and Application” key special geriatric-related biochemical diagnostic reagent quantity traceability and quality evaluation research (NO.: 2019YFF0216502).
NOTES
*Tied to the first author.